Search Results for: Athersys

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature

/ / 1 Comment
“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space even with one therapy for one targeted disease. Trials are tough […]

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature Read More »

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell

/ / 11 Comments
Athersys stock, Athersys, stem cell stocks

I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell Read More »

Weekly reads: teratoma in iPSC trial, Piero Anversa & friends, Athersys, China Initiative

/ / 1 Comment
Dr-Piero-Anversa

It’s been mostly a downbeat week on the stem cell news front including a deep revisit by Reuters to the Piero Anversa case that has new revelations. It’s ugly stuff involving other folks too. We’ll start on the iPS cell front, where a trial participant had a teratoma. I’ve had a long-standing interest in the

Weekly reads: teratoma in iPSC trial, Piero Anversa & friends, Athersys, China Initiative Read More »

Weekend recommended reads: Athersys, ALS, COVID-19, Fibroblasts, Zoom brain

/ / 3 Comments
Fibroblasts-regeneration

What are you reading these days and does it include topics like cell therapies for COVID-19, ALS, regenerative potential of fibroblasts, and why Zoom meetings are so tiring for the brain? I cover those topics and more below with recommended reads including papers and media items. Here’s last week’s recommended reads. Here’s to fibroblasts, which

Weekend recommended reads: Athersys, ALS, COVID-19, Fibroblasts, Zoom brain Read More »

Athersys & Mesoblast stem cells for COVID-19?

/ / 7 Comments
2019-nCoV-COVID-19-Pasteur

Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus disease COVID-19? Stem cells, ARDS, and COVID-19 I’ve already written two pieces about the idea of using stem cells to battle COVID-19 (here and here), the sometimes fatal disease that arises from infection with the novel coronavirus. Older patients

Athersys & Mesoblast stem cells for COVID-19? Read More »

About that Athersys stem cell stroke clinic trial PR…

/ / 12 Comments
Athersys

There has been a lot of excitement this week about a press release from stem cell biotech Athersys that reported that treatment of stroke patients with its product MultiStem was associated with a statistically significant improvement at 1-year. This sounds encouraging and the stock has spiked up as a result. However, there are some naysayers

About that Athersys stem cell stroke clinic trial PR… Read More »

20 stem cell & regenerative medicine predictions for 2024

/ / 4 Comments
Stem cell, crystal ball, predictions

Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please

20 stem cell & regenerative medicine predictions for 2024 Read More »

2023 stem cell predictions grades reflect wild year for regenerative medicine

/ / 1 Comment
stem cell predictions

Every year I make stem cell and regenerative medicine predictions. Looking at my predictions for 2023, they reflect a wild year but in many ways a good one overall. Below I have graded my 2023 predictions. Overall, my crystal ball gave solid results. Some of the predictions have been condensed to keep things concise, but you

2023 stem cell predictions grades reflect wild year for regenerative medicine Read More »

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron

/ / 5 Comments
Vericel, Cell Therapy Companies

Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy

3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »